Published in Circulation on May 10, 2010
Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol (2015) 2.87
Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol (2011) 2.02
Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. Trends Cardiovasc Med (2015) 1.54
Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol (2013) 1.20
Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J (2015) 1.09
Peripartum cardiomyopathy: a review. Tex Heart Inst J (2012) 1.06
Genetics of sudden cardiac death syndromes. Curr Opin Cardiol (2011) 1.02
Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol (2013) 1.01
Maternal cardiac metabolism in pregnancy. Cardiovasc Res (2014) 0.94
Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail (2011) 0.92
Functional characterization of TNNC1 rare variants identified in dilated cardiomyopathy. J Biol Chem (2011) 0.92
Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs. Gene (2015) 0.88
Interventions for treating peripartum cardiomyopathy to improve outcomes for women and babies. Cochrane Database Syst Rev (2010) 0.86
Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Curr Cardiol Rev (2014) 0.85
Peripartum cardiomyopathy: the need for a national database. Neth Heart J (2011) 0.84
Alcoholic cardiomyopathy. World J Cardiol (2014) 0.84
Clinical characteristics and risk factors for peripartum cardiomyopathy. Afr Health Sci (2012) 0.83
Pregnancy-Associated Heart Failure: A Comparison of Clinical Presentation and Outcome between Hypertensive Heart Failure of Pregnancy and Idiopathic Peripartum Cardiomyopathy. PLoS One (2015) 0.82
Birthing the genetics of peripartum cardiomyopathy. Circulation (2010) 0.81
Peripartum cardiomyopathy: a contemporary review. Methodist Debakey Cardiovasc J (2013) 0.80
Impact of Mendelian inheritance in cardiovascular disease. Ann N Y Acad Sci (2010) 0.80
Peripartum cardiomyopathy: moving towards a more central role of genetics. Curr Cardiol Rev (2013) 0.79
Peripartum cardiomyopathy: Euro Observational Research Program. Neth Heart J (2014) 0.78
A change of heart: case series of peripartum cardiomyopathy. Case Rep Obstet Gynecol (2013) 0.77
Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart (2014) 0.76
Peripartum cardiomyopathy and dilated cardiomyopathy: different at heart. Front Physiol (2015) 0.76
Role of multimodality imaging in ischemic and non-ischemic cardiomyopathy. Heart Fail Rev (2011) 0.76
Letter by Baruteau et al regarding article, "Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy". Circulation (2011) 0.75
Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. Acta Inform Med (2011) 0.75
Peripartum cardiomyopathy. Ann Med Health Sci Res (2013) 0.75
Beware Postpartum Shortness of Breath. Pak J Med Sci (2015) 0.75
Lactation Is a Risk Factor of Postpartum Heart Failure in Mice with Cardiomyocyte-specific Apelin Receptor (APJ) Overexpression. J Biol Chem (2016) 0.75
Article Commentary: Acute Heart Failure: Is it Peripartum Cardiomyopathy or Not? Obstet Med (2013) 0.75
Practical management of peripartum cardiomyopathy. Korean J Intern Med (2017) 0.75
Insights and Challenges of Multi-Scale Modeling of Sarcomere Mechanics in cTn and Tm DCM Mutants-Genotype to Cellular Phenotype. Front Physiol (2017) 0.75
Changes in the Dynamics of the Cardiac Troponin C Molecule Explain the Effects of Ca(2+)-Sensitizing Mutations. J Biol Chem (2017) 0.75
Clinical Application of Genetic Testing in Heart Failure. Curr Heart Fail Rep (2017) 0.75
Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res (2017) 0.75
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med (2004) 6.00
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol (2013) 3.54
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol (2010) 3.50
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Aortic stenosis. Lancet (2009) 3.37
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol (2009) 3.31
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol (2005) 3.29
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation (2007) 3.12
Myocardial structure and function differ in systolic and diastolic heart failure. Circulation (2006) 3.11
Common variants near TERC are associated with mean telomere length. Nat Genet (2010) 2.98
Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J (2005) 2.81
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail (2007) 2.77
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J (2005) 2.74
Proteomics of protein secretion by Bacillus subtilis: separating the "secrets" of the secretome. Microbiol Mol Biol Rev (2004) 2.67
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol (2008) 2.59
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol (2010) 2.51
Subcellular sites for bacterial protein export. Mol Microbiol (2004) 2.50
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J (2013) 2.45
Cardiomyocyte stiffness in diastolic heart failure. Circulation (2005) 2.43
Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation. Circ Res (2009) 2.41
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J (2013) 2.37
What mechanisms underlie diastolic dysfunction in heart failure? Circ Res (2004) 2.36
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.36
Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation (2006) 2.35
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol (2011) 2.31
Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med (2009) 2.31
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation (2004) 2.30
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J (2008) 2.26
Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med (2008) 2.23
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Endogenous erythropoietin and outcome in heart failure. Circulation (2010) 2.19
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation (2012) 2.14
Activation delay and VT parameters in arrhythmogenic right ventricular dysplasia/cardiomyopathy: toward improvement of diagnostic ECG criteria. J Cardiovasc Electrophysiol (2008) 2.09
The European cardiac resynchronization therapy survey. Eur Heart J (2009) 2.04
A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet (2002) 2.02
Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation (2009) 2.01
Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol (2007) 2.00
Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res (2009) 1.99
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet (2015) 1.94
Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail (2009) 1.93
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91
Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail (2007) 1.91
Remodeling of the cardiac sodium channel, connexin43, and plakoglobin at the intercalated disk in patients with arrhythmogenic cardiomyopathy. Heart Rhythm (2012) 1.91
Desmin mutations as a cause of right ventricular heart failure affect the intercalated disks. Heart Rhythm (2010) 1.85
Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat (2013) 1.85
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83
Identification and functional characterization of cardiac troponin I as a novel disease gene in autosomal dominant dilated cardiomyopathy. Circ Res (2009) 1.83
Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm (2009) 1.78
Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation (2007) 1.74
Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest (2007) 1.74
Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J (2009) 1.73
Cardiac beta-myosin heavy chain defects in two families with non-compaction cardiomyopathy: linking non-compaction to hypertrophic, restrictive, and dilated cardiomyopathies. Eur Heart J (2007) 1.72
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol (2012) 1.71
Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging (2009) 1.70